BR0317026A - Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares - Google Patents
Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças ocularesInfo
- Publication number
- BR0317026A BR0317026A BR0317026-8A BR0317026A BR0317026A BR 0317026 A BR0317026 A BR 0317026A BR 0317026 A BR0317026 A BR 0317026A BR 0317026 A BR0317026 A BR 0317026A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- superoxide dismutase
- diseases
- eye disorders
- dismutase mimics
- Prior art date
Links
- 102000019197 Superoxide Dismutase Human genes 0.000 title abstract 2
- 108010012715 Superoxide dismutase Proteins 0.000 title abstract 2
- 208000030533 eye disease Diseases 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 201000010183 Papilledema Diseases 0.000 abstract 1
- 206010038886 Retinal oedema Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- 201000011195 retinal edema Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43140102P | 2002-12-06 | 2002-12-06 | |
| PCT/US2003/038678 WO2004052227A2 (en) | 2002-12-06 | 2003-12-05 | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0317026A true BR0317026A (pt) | 2005-10-25 |
Family
ID=32507723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0317026-8A BR0317026A (pt) | 2002-12-06 | 2003-12-05 | Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060089343A1 (enExample) |
| EP (1) | EP1581212A4 (enExample) |
| JP (1) | JP2006510669A (enExample) |
| CN (1) | CN1717234A (enExample) |
| AU (1) | AU2003298917A1 (enExample) |
| BR (1) | BR0317026A (enExample) |
| CA (1) | CA2505608A1 (enExample) |
| MX (1) | MXPA05005240A (enExample) |
| WO (1) | WO2004052227A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| WO2006033734A2 (en) * | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| WO2006091796A2 (en) * | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
| MX2009011360A (es) | 2007-04-20 | 2010-02-12 | Acucela Inc | Compuestos derivados de estirenilo para tratar enfermedades y trastornos oftalmicos. |
| CA2690229C (en) | 2007-06-29 | 2013-10-29 | Acucela, Inc. | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| WO2009045479A1 (en) | 2007-10-05 | 2009-04-09 | Acucela Inc. | Alkoxy compounds for disease treatment |
| JP5559701B2 (ja) * | 2008-01-30 | 2014-07-23 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | イミダゾリウム及びイミダゾリニウム化合物で線維症及び癌を治療する方法 |
| WO2009123569A1 (en) * | 2008-03-31 | 2009-10-08 | Agency For Science, Technology And Research | Method for treating neurological disorders with imidazolium and imidazolinium compounds |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| AU2010313249B2 (en) | 2009-10-30 | 2016-05-19 | Biojiva Llc | Alleviating oxidative stress disorders with PUFA derivatives |
| EP2433640B1 (en) | 2010-09-24 | 2020-01-15 | OmniVision GmbH | Composition comprising SOD, lutein and zeaxanthin |
| US10154983B2 (en) | 2011-04-26 | 2018-12-18 | Retrotope, Inc. | Neurodegenerative disorders and muscle diseases implicating PUFAs |
| CA2834342C (en) | 2011-04-26 | 2021-08-31 | Retrotope, Inc. | Impaired energy processing disorders and mitochondrial deficiency |
| DK2701697T3 (da) | 2011-04-26 | 2020-06-29 | Retrotope Inc | Oxidative nethindesygdomme |
| KR102110175B1 (ko) | 2011-04-26 | 2020-05-13 | 레트로토프 인코포레이티드 | Ｐｕｆａ 산화와 관련된 장애 |
| WO2013109991A1 (en) | 2012-01-20 | 2013-07-25 | Acucela Inc. | Substituted heterocyclic compounds for disease treatment |
| EP2911662A4 (en) * | 2012-10-25 | 2016-09-28 | Technion Res & Dev Foundation | METHOD OF TREATING A DISEASE |
| BR112015022041A2 (pt) | 2013-03-12 | 2017-07-18 | Acucela Inc | derivados substituídos de 3-fenilpropilamina para o tratamento de doenças e distúrbios oftálmicas |
| EP3950649A1 (en) | 2015-11-23 | 2022-02-09 | Retrotope, Inc. | Site-specific isotopic labeling of 1, 4-diene systems |
| KR20220143931A (ko) | 2020-02-21 | 2022-10-25 | 레트로토프 인코포레이티드 | 고도불포화 지방산 및 이의 유도체의 동위원소 변형을 위한 공정 |
| US12109194B2 (en) | 2021-02-05 | 2024-10-08 | Biojiva Llc | Synergistic combination therapy for treating ALS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252720A (en) * | 1989-03-06 | 1993-10-12 | Board Of Regents, The University Of Texas System | Metal complexes of water soluble texaphyrins |
| TW325997B (en) * | 1993-02-02 | 1998-02-01 | Senju Pharma Co | Pharmaceutical composition for preventing and treating retinal diseases |
| US6127356A (en) * | 1993-10-15 | 2000-10-03 | Duke University | Oxidant scavengers |
| US5994339A (en) * | 1993-10-15 | 1999-11-30 | University Of Alabama At Birmingham Research Foundation | Oxidant scavengers |
| US5798349A (en) * | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| US6214817B1 (en) * | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
| US6180620B1 (en) * | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
| CA2309154C (en) * | 1997-11-03 | 2010-02-16 | Duke University | Substituted porphyrins |
| GB9817845D0 (en) * | 1998-08-17 | 1998-10-14 | Glaxo Group Ltd | Chemical compounds |
| ATE552260T1 (de) * | 1999-01-25 | 2012-04-15 | Nat Jewish Health | Substituierte porphyrine und deren therapeutische verwendung |
| AU2002312194B8 (en) * | 2001-06-01 | 2008-05-15 | Aeolus Sciences, Inc. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
-
2003
- 2003-12-05 CN CNA2003801041193A patent/CN1717234A/zh active Pending
- 2003-12-05 AU AU2003298917A patent/AU2003298917A1/en not_active Abandoned
- 2003-12-05 WO PCT/US2003/038678 patent/WO2004052227A2/en not_active Ceased
- 2003-12-05 US US10/534,791 patent/US20060089343A1/en not_active Abandoned
- 2003-12-05 EP EP03796677A patent/EP1581212A4/en not_active Withdrawn
- 2003-12-05 JP JP2004559315A patent/JP2006510669A/ja active Pending
- 2003-12-05 MX MXPA05005240A patent/MXPA05005240A/es unknown
- 2003-12-05 CA CA002505608A patent/CA2505608A1/en not_active Abandoned
- 2003-12-05 US US10/729,213 patent/US20040116403A1/en not_active Abandoned
- 2003-12-05 BR BR0317026-8A patent/BR0317026A/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006510669A (ja) | 2006-03-30 |
| CN1717234A (zh) | 2006-01-04 |
| EP1581212A4 (en) | 2008-11-05 |
| CA2505608A1 (en) | 2004-06-24 |
| US20060089343A1 (en) | 2006-04-27 |
| US20040116403A1 (en) | 2004-06-17 |
| WO2004052227A2 (en) | 2004-06-24 |
| AU2003298917A1 (en) | 2004-06-30 |
| WO2004052227A3 (en) | 2005-03-31 |
| MXPA05005240A (es) | 2005-07-25 |
| EP1581212A2 (en) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0317026A (pt) | Mìmicos de superóxido dismutase para o tratamento de distúrbios e doenças oculares | |
| CY1108983T1 (el) | Μιμητικα της υπεροξειδικης δισμουτασης για την αγωγη οφθαλμικων διαταραχων και νοσων | |
| DE60119784D1 (de) | Cyclische salen metall verbindungen als einfänger von sauerstoffradikalen und verwendbar als antioxidantien bei der behandlung und vorbeugung von krankheiten | |
| DE60334134D1 (de) | Ungsmethode von erhöhtem augeninnendruck und glaukom | |
| MX2010002889A (es) | Estructura de soporte de respirador de pieza facial filtrante que tiene bisagras activas. | |
| MX2007004862A (es) | Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias. | |
| WO2004096216A3 (en) | Use of a topical medicament comprising riluzole | |
| AU2002236100A1 (en) | New therapeutic uses of smr1 peptides | |
| WO2006100677A3 (en) | Device and method for pupil size modulation | |
| WO2002067971A3 (en) | Use of endostatin in the treatment of ocular neovascularization | |
| BR0013793A (pt) | Medicamentos profiláticos e terapêuticos para doenças oftálmicas | |
| DE60233350D1 (de) | IMIDAZOi2,1-B -1,3,4-THIADIAZOLE SULFONAMIDES | |
| BR0017163A (pt) | Derivados 5-hidróxi-indazol para tratamento do glaucoma | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| EP1567166A4 (en) | SUPEROXIDE DISMUTASE MIMIC FOR THE TREATMENT OF EYE DISORDER AND DISEASES | |
| MXPA06012143A (es) | Arilsulfonamidas y usos relacionados con las mismas. | |
| AU2001267864A1 (en) | Remedial agent for optic nerve disease and the like | |
| ZA200703992B (en) | 5, 6, 7-Trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses | |
| BRPI0417549A (pt) | miméticos de superóxido dismutase para o tratamento de lesão de nervo óptico e retinal | |
| TR200402299T4 (tr) | Alerjik hastalıkların tedavisi için anilin disülfit türevleri | |
| BRPI0412212A (pt) | uso da dapsona como neuroprotetor no infarto cerebral | |
| MXPA05012696A (es) | Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica. | |
| TW200600099A (en) | Therapeutic or preventive agent for eye disease | |
| HK1084315A (en) | Superoxide dismutase mimics for the treatment of ocular disorders and diseases | |
| TR201900152T4 (tr) | Sinükleinopatik ve amiloidojenik hastalıkların önlenmesi ve tedavisi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B15L | Others concerning applications: renumbering |
Free format text: RENUMERADO PARA PI 0310138-0 |